Ambrisentan ameliorated isoprenaline-induced biochemical and histological changes in rats, likely via selective inhibition of the ET1A receptor and modulation of inflammatory and apoptotic pathways.
Does ambrisentan alleviate isoprenaline-induced myocardial injury in rats?
Ambrisentan alleviates isoprenaline-induced myocardial injury in a rat model through anti-inflammatory, anti-apoptotic, and antioxidant mechanisms via modulation of the ET1/NF-κB/IL-6/STAT-4/AP-1 pathway.
BACKGROUND: Myocardial injury stands as the foremost contributing factor in raising morbidity and mortality within the realm of cardiac diseases worldwide. Nowadays, there is no available treatment to completely rescue the myocardium. Thus, we aimed to study the possible role of ambrisentan (AMB) in experimentally induced myocardial damage using a highly toxic dose of isoprenaline (ISO) (150 mg/kg). METHODOLOGY: Rats were randomly divided into five groups: control, ISO given groups, which were administered alone or in combination with AMB in 3 different doses (10, 20, 30 mg/kg/day). RESULTS: activator protein-1 (AP-1) pathway. However, co-administration of AMB could ameliorate ISO-induced biochemical and histological changes. CONCLUSION: We concluded that AMB successfully diminished ISO-induced injury likely due to its main pharmacological action of selective inhibition on ET1A receptor, modulation of ET1/NF-κB/IL-6/STAT-4/AP-1 signaling pathways with anti-inflammatory, anti-apoptotic and antioxidant properties.
Refaie et al. (Thu,) conducted a other in Isoprenaline-induced myocardial injury. Ambrisentan (AMB) vs. Control and isoprenaline alone was evaluated on Biochemical and histological changes. Ambrisentan ameliorated isoprenaline-induced biochemical and histological changes in rats, likely via selective inhibition of the ET1A receptor and modulation of inflammatory and apoptotic pathways.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: